ALT Title slide by the ME/CFS Research Foundation reading: New guest article. The Top 100 therapeutic trials in PAIS. Is the next blockbuster market taking shape? Below, a note that the article gives an overview of the current state of therapy development in post-acute infection syndromes, including ME/CFS, Long COVID, POTS and fibromyalgia, followed by the author line by Dr. Fred Dejonckheere.

ALT Text slide headed: Why does this article matter now? It lists five points: many millions of people affected worldwide, enormous societal costs and challenges, research growing steadily with 20 percent more Long COVID publications per year, inadequate care for patients and still no approved disease-modifying drug, and public initiatives starting, in Germany with 50 million euros a year for 10 years of PAIS research and at EU level as well. The closing line reads: the waiting is over, PAIS is the next therapeutic frontier with high unmet need.

ALT Text slide headed: Why PAIS is a blue ocean market. It lists five points: large unmet need with millions of people worldwide left without care, high pricing power because no disease-modifying therapies are approved, no winner-takes-all risk because complex diseases require diverse and combined approaches, several novel mechanisms of action in the pipeline rather than a pure me-too race, and global momentum with strong patient voices calling for accelerated research and investment. The closing line reads: the first approval of a novel therapy could open a multi-billion market and improve millions of lives.

ALT Closing slide headed: Read the full article now. It lists four points: a detailed analysis of the Top 100 interventions, insights into seven key categories of mechanisms of action plus diagnostics and precision medicine, 2025 data based on global clinical trial registries, and a note that the article is written for researchers, clinicians and everyone who wants to make change happen. Below, a note that the Top 100 list in English is linked for download inside the article, and a note that the interventions listed are not a treatment recommendation. At the bottom, the logo and claim of the ME/CFS Research Foundation: We fund research. We inform. We move things forward.